Precision Oncogenomics

The Journal of Precision Oncogenomics, a new Taylor and Francis Journal is launching with a call for a special article collection with a theme of “Precision Medicine in Haemato-Oncology”. This themed issue welcomes research articles and reviews with a focus on developing and evaluating precision medicine for haematological malignancies.

Precision medicine has developed substantially since the discovery of imatinib for chronic myeloid leukaemia (CML) and numerous examples of targeted therapies exist for solid tumours (e.g., trastuzumab for HER2 positive breast cancers; the ALK inhibitor crizotinib for lung cancer). Over the past 10 years, several novel targeted therapies have been FDA-approved that target haematologic cancer, some examples of which include enasidenib and ivosidenib, two small molecule inhibitors targeting IDH2 and IDH1 gene mutations, respectively, and gilteritinib for relapsed/refractory FLT3 mutation-positive acute myeloid leukaemia (AML). The development of large scale -omics as precision diagnostic tools, along with functional screening technologies, has led to a new era of precision medicine in haemato-oncology.

Although progress has been made several challenges remain, including:

• The intricacy of treating clonally complex diseases
• A dearth of precision medicines with the ability to target all common ‘drivers’ in leukaemias and lymphomas
• The ability to detect measurable residual disease (MRD) and to interject clinically at earlier time points to circumvent relapse
• How to meaningfully evaluate targeted agents in small subsets of patients with rare driver mutations
• Assessing the contribution of the microenvironment in drug sensitivity and resistance

This Article Collection will cover all types of haematological malignancies in pediatric and adult patients and solicit manuscripts related to the following subjects. However, we welcome all submissions related to the “Precision Medicine in Haemato-Oncology” theme:

• Development and application of -omics technologies (genomics, transcriptomics, epigenomics, proteomics) as precision diagnostic tools in haematological malignancies
• Integration of -omics and functional screening to identify novel targetable pathways in subsets of leukaemias and lymphomas
• Harnessing functional precision medicine in haematology to evaluate combination therapies and to study drug resistance
• New approaches for sensitive disease monitoring and the utility of single-cell technologies in evaluating haematologic cancers and the biology of measurable residual disease (MRD)
• Novel clinical trial concepts focused on interceding at earlier time points during disease relapse

Instructions for Authors

The following Article Types will be considered: basic and clinical original research, meta-analyses, systematic reviews, narrative reviews, and commentaries.

When submitting your article, please select the Article Collection, ‘Precision Medicine in Haemato-oncology’ from the drop-down menu on the submission system.

Instructions for AuthorsSubmit an Article